Better outcomes and fewer failures drive innovation in rheumatoid arthritis
This article was originally published in Scrip
Executive Summary
While market-leading anti-tumor necrosis factor (TNF) agents such as Humira (adalimumab; AbbVie/Eisai) and Enbrel (etanercept; Amgen/Pfizer/Takeda) have revolutionized the treatment of rheumatoid arthritis, there continues to be a significant unmet need for novel therapies that are associated with fewer treatment failures and inadequate responders. Recent Datamonitor Healthcare analysis of the early phase rheumatoid arthritis pipeline has identified the most commercially attractive opportunities in this therapy area, all still at a relatively early stage of investigation. "Recent innovation in the rheumatoid arthritis market is focused on demonstrating a superior clinical profile to the well-established anti-TNFs through biologics with novel mechanisms of action or novel oral small molecules," Datamonitor Healthcare analyst Christina Vasiliou told Scrip.